Amberstone Biosciences and Henlius Enter into Collaboration and License Agreement for Conditionally Activated T-Cell Engagers for Solid Tumors

IRVINE, Calif., Sept. 24, 2026 /PRNewswire/ -- Amberstone Biosciences, Inc., a preclinical-stage oncology company developing pH-gated, tumor-activated T-cell engagers (TCEs), today announced a collaboration and license agreement with Shanghai Henlius Biotech, Inc., a commercial-stage...